AKR1B10 Human (4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid multiple interactions EXP 6480464 zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] and zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 AKR1B10 Human (4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid decreases activity EXP 6480464 zopolrestat results in decreased activity of AKR1B10 protein and zopolrestat results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 AKR1B10 Human (E)-cinnamyl alcohol increases expression EXP 6480464 cinnamyl alcohol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human (E,E)-2,4-hexadienal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 2 more ... CTD PMID:21329684 AKR1B10 Human (R)-acetoin increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Acetoin CTD PMID:23295224 AKR1B10 Human (R)-acetoin multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2 more ... CTD PMID:23295224 AKR1B10 Human 1,2-dimethylhydrazine increases expression ISO Akr1b10 (Mus musculus) 6480464 1 and 2-Dimethylhydrazine results in increased expression of AKR1B10 mRNA CTD PMID:22206623 AKR1B10 Human 1-chloro-2,4-dinitrobenzene increases expression EXP 6480464 Dinitrochlorobenzene results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human 13-dihydrodaunorubicin multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol CTD PMID:19028477 AKR1B10 Human 17beta-estradiol decreases expression EXP 6480464 Estradiol results in decreased expression of AKR1B10 mRNA CTD PMID:25321415 AKR1B10 Human 17beta-estradiol multiple interactions ISO Akr1b10 (Rattus norvegicus) 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of AKR1B10 mRNA CTD PMID:26496021 AKR1B10 Human 17beta-estradiol multiple interactions EXP 6480464 [Estradiol co-treated with TGFB1 protein] results in decreased expression of AKR1B10 mRNA and [Progesterone co-treated with Estradiol] results in decreased expression of AKR1B10 mRNA CTD PMID:17404688 and PMID:30165855 AKR1B10 Human 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of AKR1B10 mRNA CTD PMID:20106945 more ... AKR1B10 Human 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Tetrachlorodibenzodioxin results in decreased expression of AKR1B10 mRNA CTD PMID:33387578 AKR1B10 Human 2-(chloromethyl)pyridine increases expression EXP 6480464 2-chloromethylpyridine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human 2-acetamidofluorene multiple interactions ISO Akr1b10 (Rattus norvegicus) 6480464 [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of AKR1B10 mRNA CTD PMID:14656948 AKR1B10 Human 2-acetamidofluorene increases expression EXP 6480464 2-Acetylaminofluorene results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human 2-hexenal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 2-hexenal and AKR1B10 protein results in increased reduction of 2-hexenal metabolite CTD PMID:21329684 AKR1B10 Human 2-hydroxypropanoic acid increases expression EXP 6480464 Lactic Acid results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human 2-hydroxypropanoic acid decreases expression EXP 6480464 Lactic Acid results in decreased expression of AKR1B10 mRNA CTD PMID:30851411 AKR1B10 Human 2-palmitoylglycerol increases expression EXP 6480464 2-palmitoylglycerol results in increased expression of AKR1B10 mRNA CTD PMID:37199045 AKR1B10 Human 2-tert-butylhydroquinone increases expression EXP 6480464 2-tert-butylhydroquinone results in increased expression of AKR1B10 mRNA CTD PMID:30806763 AKR1B10 Human 3-chloropropane-1,2-diol increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 alpha-Chlorohydrin results in increased expression of AKR1B10 mRNA CTD PMID:28522335 AKR1B10 Human 3-Hydroxybenzo[a]pyrene increases expression EXP 6480464 3-hydroxybenzo(a)pyrene results in increased expression of AKR1B10 mRNA CTD PMID:26238291 AKR1B10 Human 3-methyl-3H-imidazo[4,5-f]quinolin-2-amine decreases expression EXP 6480464 2-amino-3-methylimidazo(4 and 5-f)quinoline results in decreased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human 3-phenylprop-2-enal increases expression EXP 6480464 cinnamaldehyde results in increased expression of AKR1B10 mRNA CTD PMID:30806763 AKR1B10 Human 4,4'-methylene-bis-(2-chloroaniline) increases expression EXP 6480464 Methylenebis(chloroaniline) results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human 4,4'-sulfonyldiphenol increases expression ISO Akr1b10 (Mus musculus) 6480464 bisphenol S results in increased expression of AKR1B10 mRNA CTD PMID:30951980 AKR1B10 Human 4-hydroperoxycyclophosphamide affects response to substance EXP 6480464 AKR1B10 protein affects the susceptibility to perfosfamide CTD PMID:18473730 AKR1B10 Human 4-hydroxynon-2-enal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 4-hydroxy-2-nonenal CTD PMID:19013440 and PMID:21329684 AKR1B10 Human 4-hydroxynon-2-enal increases metabolic processing EXP 6480464 AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal CTD PMID:27417252 AKR1B10 Human 4-hydroxynon-2-enal multiple interactions EXP 6480464 Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal] CTD PMID:27417252 AKR1B10 Human 4-hydroxyphenyl retinamide increases expression ISO Akr1b10 (Mus musculus) 6480464 Fenretinide results in increased expression of AKR1B10 mRNA CTD PMID:28973697 AKR1B10 Human 4-methylpentanal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of isocaproaldehyde CTD PMID:19013440 AKR1B10 Human 4-nitro-1,2-phenylenediamine increases expression EXP 6480464 1 and 2-diamino-4-nitrobenzene results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human 5-fluorouracil affects expression EXP 6480464 Fluorouracil affects the expression of AKR1B10 mRNA CTD PMID:16584549 AKR1B10 Human 7,12-dimethyltetraphene increases expression EXP 6480464 9 more ... CTD PMID:26198647 AKR1B10 Human 9,10-phenanthroquinone increases metabolic processing EXP 6480464 AKR1B10 protein results in increased metabolism of 9 and 10-phenanthrenequinone CTD PMID:24813866 AKR1B10 Human 9,10-phenanthroquinone increases expression EXP 6480464 9 and 10-phenanthrenequinone results in increased expression of AKR1B10 mRNA CTD PMID:24813866 AKR1B10 Human 9-cis-retinal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 9-cis-retinal CTD PMID:21851338 AKR1B10 Human [6]-Shogaol increases expression EXP 6480464 shogaol metabolite results in increased expression of AKR1B10 protein more ... CTD PMID:25148906 AKR1B10 Human acetoin multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2 more ... CTD PMID:23295224 AKR1B10 Human acetoin increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Acetoin CTD PMID:23295224 AKR1B10 Human acrolein affects metabolic processing EXP 6480464 Acrolein affects the metabolism of AKR1B10 protein and AKR1B10 protein affects the metabolism of Acrolein CTD PMID:17329238 and PMID:17597105 AKR1B10 Human acrolein increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Acrolein results in increased expression of AKR1B10 mRNA CTD PMID:38090360 AKR1B10 Human acrolein increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Acrolein and AKR1B10 protein results in increased reduction of Acrolein metabolite CTD PMID:21329684 AKR1B10 Human acrolein decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Acrolein CTD PMID:17329238 and PMID:17597105 AKR1B10 Human actinomycin D multiple interactions EXP 6480464 [Dactinomycin co-treated with nutlin 3] results in increased secretion of AKR1B10 protein CTD PMID:38460933 AKR1B10 Human adhumulone decreases activity EXP 6480464 adhumulone results in decreased activity of AKR1B10 protein CTD PMID:30469331 AKR1B10 Human aflatoxin B1 increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Aflatoxin B1 results in increased expression of AKR1B10 mRNA CTD PMID:23630614 and PMID:25378103 AKR1B10 Human aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of AKR1B10 mRNA CTD PMID:32234424 AKR1B10 Human all-trans-4-oxoretinal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 4-oxoretinaldehyde CTD PMID:19014918 AKR1B10 Human all-trans-dehydroretinal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of dehydroretinal CTD PMID:19014918 AKR1B10 Human all-trans-retinal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Retinaldehyde CTD PMID:19014918 AKR1B10 Human all-trans-retinal increases metabolic processing EXP 6480464 AKR1B10 protein results in increased metabolism of Retinaldehyde CTD PMID:21329680 AKR1B10 Human all-trans-retinol decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Vitamin A and AKR1B10 protein results in decreased susceptibility to Vitamin A metabolite CTD PMID:19014918 AKR1B10 Human Aloe emodin decreases activity EXP 6480464 aloe emodin results in decreased activity of AKR1B10 protein CTD PMID:35065925 AKR1B10 Human alpha-hexylcinnamaldehyde increases expression EXP 6480464 hexyl cinnamic aldehyde results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human amoxicillin increases expression EXP 6480464 Amoxicillin results in increased expression of AKR1B10 mRNA CTD PMID:28444390 AKR1B10 Human ampicillin decreases expression EXP 6480464 Ampicillin results in decreased expression of AKR1B10 mRNA CTD PMID:21632981 and PMID:26198647 AKR1B10 Human anthranilic acid increases expression EXP 6480464 anthranilic acid results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human antimonite multiple interactions EXP 6480464 [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 AKR1B10 Human arsane multiple interactions EXP 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA CTD PMID:32525701 AKR1B10 Human arsane increases expression EXP 6480464 Arsenic results in increased expression of AKR1B10 mRNA CTD PMID:36861143 AKR1B10 Human arsenic atom multiple interactions EXP 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA CTD PMID:32525701 AKR1B10 Human arsenic atom increases expression EXP 6480464 Arsenic results in increased expression of AKR1B10 mRNA CTD PMID:36861143 AKR1B10 Human arsenite(3-) multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 AKR1B10 Human arsenous acid decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Arsenic Trioxide CTD PMID:20707922 AKR1B10 Human atrazine increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Atrazine results in increased expression of AKR1B10 mRNA CTD PMID:36841081 AKR1B10 Human Augmentin increases expression EXP 6480464 Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA CTD PMID:34767876 AKR1B10 Human azathioprine increases expression EXP 6480464 Azathioprine results in increased expression of AKR1B10 mRNA CTD PMID:22623647 and PMID:26198647 AKR1B10 Human Bandrowski's base increases expression EXP 6480464 Bandrowski's base results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human benzalkonium chloride increases expression EXP 6480464 Benzalkonium Compounds results in increased expression of AKR1B10 mRNA CTD PMID:30806763 AKR1B10 Human benzidine increases expression EXP 6480464 benzidine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human benzo[a]pyrene decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Benzo(a)pyrene results in decreased expression of AKR1B10 mRNA CTD PMID:21839799 AKR1B10 Human benzo[a]pyrene increases methylation EXP 6480464 Benzo(a)pyrene results in increased methylation of AKR1B10 promoter CTD PMID:27901495 AKR1B10 Human benzo[a]pyrene affects methylation EXP 6480464 Benzo(a)pyrene affects the methylation of AKR1B10 exon CTD PMID:27901495 AKR1B10 Human benzo[a]pyrene increases expression ISO Akr1b10 (Mus musculus) 6480464 Benzo(a)pyrene results in increased expression of AKR1B10 mRNA CTD PMID:19770486 AKR1B10 Human benzo[a]pyrene increases expression EXP 6480464 Benzo(a)pyrene results in increased expression of AKR1B10 mRNA and Benzo(a)pyrene results in increased expression of AKR1B10 protein CTD PMID:16545412 more ... AKR1B10 Human Benzo[a]pyrene-7,8-diol multiple interactions EXP 6480464 [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7 and 8-dihydrodiol CTD PMID:21910479 AKR1B10 Human benzo[a]pyrene-7,8-dione multiple interactions EXP 6480464 [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7 and 8-dione CTD PMID:21910479 AKR1B10 Human benzoic acid increases expression EXP 6480464 Benzoic Acid results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human beta-lapachone increases expression EXP 6480464 beta-lapachone results in increased expression of AKR1B10 mRNA CTD PMID:38218311 AKR1B10 Human bis(2-chloroethyl) sulfide increases expression EXP 6480464 Mustard Gas results in increased expression of AKR1B10 mRNA CTD PMID:25102026 AKR1B10 Human bis(2-ethylhexyl) phthalate increases expression EXP 6480464 Diethylhexyl Phthalate results in increased expression of AKR1B10 mRNA CTD PMID:28412506 AKR1B10 Human bisphenol A multiple interactions ISO Akr1b10 (Mus musculus) 6480464 [potassium bromate co-treated with bisphenol A] affects the expression of AKR1B10 mRNA and [XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of AKR1B10 mRNA] CTD PMID:27082013 AKR1B10 Human bisphenol A increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 bisphenol A results in increased expression of AKR1B10 mRNA CTD PMID:30816183 AKR1B10 Human bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of AKR1B10 mRNA CTD PMID:30903817 AKR1B10 Human bisphenol A increases methylation ISO Akr1b10 (Rattus norvegicus) 6480464 bisphenol A results in increased methylation of AKR1B10 gene CTD PMID:28505145 AKR1B10 Human bisphenol A decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 bisphenol A results in decreased expression of AKR1B10 mRNA CTD PMID:25181051 AKR1B10 Human bisphenol A multiple interactions ISO Akr1b10 (Rattus norvegicus) 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of AKR1B10 mRNA CTD PMID:26496021 AKR1B10 Human bortezomib increases expression EXP 6480464 Bortezomib results in increased expression of AKR1B10 mRNA and Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 AKR1B10 Human butane-2,3-diol multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2 and 3-butylene glycol CTD PMID:23295224 AKR1B10 Human butane-2,3-dione increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Diacetyl CTD PMID:23295224 AKR1B10 Human butane-2,3-dione multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin CTD PMID:23295224 AKR1B10 Human cadmium atom increases expression EXP 6480464 Cadmium results in increased expression of AKR1B10 mRNA CTD PMID:21120746 and PMID:21172416 AKR1B10 Human cadmium sulfate multiple interactions EXP 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA CTD PMID:18654764 AKR1B10 Human captan increases expression ISO Akr1b10 (Mus musculus) 6480464 Captan results in increased expression of AKR1B10 mRNA CTD PMID:31558096 AKR1B10 Human carbamazepine affects expression EXP 6480464 Carbamazepine affects the expression of AKR1B10 mRNA CTD PMID:25979313 AKR1B10 Human carbon nanotube decreases expression ISO Akr1b10 (Mus musculus) 6480464 Nanotubes more ... CTD PMID:25554681 AKR1B10 Human chlorambucil decreases expression EXP 6480464 Chlorambucil results in decreased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human chromium(6+) multiple interactions EXP 6480464 [zinc chromate results in increased abundance of chromium hexavalent ion] which results in increased expression of AKR1B10 mRNA CTD PMID:38479592 AKR1B10 Human chrysin decreases expression EXP 6480464 chrysin results in decreased expression of AKR1B10 mRNA and chrysin results in decreased expression of AKR1B10 protein CTD PMID:23994249 AKR1B10 Human cinnamyl alcohol increases expression EXP 6480464 cinnamyl alcohol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human ciprofibrate multiple interactions EXP 6480464 ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] and ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 AKR1B10 Human ciprofibrate decreases activity EXP 6480464 ciprofibrate results in decreased activity of AKR1B10 protein and ciprofibrate results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 AKR1B10 Human cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of AKR1B10 mRNA CTD PMID:19561079 and PMID:27392435 AKR1B10 Human cisplatin multiple interactions EXP 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of AKR1B10 mRNA CTD PMID:27392435 AKR1B10 Human cisplatin decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Cisplatin CTD PMID:27417252 AKR1B10 Human clavulanic acid increases expression EXP 6480464 Clavulanic Acid results in increased expression of AKR1B10 mRNA CTD PMID:34767876 AKR1B10 Human Clofop decreases activity EXP 6480464 fenofibric acid results in decreased activity of AKR1B10 protein and fenofibric acid results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 AKR1B10 Human Clofop multiple interactions EXP 6480464 fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] and fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 AKR1B10 Human cobalt dichloride multiple interactions EXP 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA CTD PMID:18654764 AKR1B10 Human Cohumulone decreases activity EXP 6480464 cohumulone results in decreased activity of AKR1B10 protein CTD PMID:30469331 AKR1B10 Human copper atom multiple interactions EXP 6480464 [NSC 689534 binds to Copper] which results in increased expression of AKR1B10 mRNA CTD PMID:20971185 AKR1B10 Human copper(0) multiple interactions EXP 6480464 [NSC 689534 binds to Copper] which results in increased expression of AKR1B10 mRNA CTD PMID:20971185 AKR1B10 Human copper(II) chloride increases expression EXP 6480464 cupric chloride results in increased expression of AKR1B10 mRNA CTD PMID:38568856 AKR1B10 Human copper(II) sulfate increases expression EXP 6480464 Copper Sulfate results in increased expression of AKR1B10 mRNA CTD PMID:19549813 AKR1B10 Human crotonaldehyde affects metabolic processing EXP 6480464 2-butenal affects the metabolism of AKR1B10 protein CTD PMID:17597105 AKR1B10 Human crotonaldehyde increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 2-butenal and AKR1B10 protein results in increased reduction of 2-butenal metabolite CTD PMID:21329684 AKR1B10 Human crotonaldehyde decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to 2-butenal CTD PMID:17597105 AKR1B10 Human cyclosporin A increases expression EXP 6480464 Cyclosporine results in increased expression of AKR1B10 mRNA CTD PMID:25562108 AKR1B10 Human cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of AKR1B10 mRNA CTD PMID:27989131 AKR1B10 Human D-glyceraldehyde multiple interactions EXP 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 and PMID:19028477 AKR1B10 Human D-glyceraldehyde decreases activity EXP 6480464 Glyceraldehyde results in decreased activity of AKR1B10 protein CTD PMID:30469331 AKR1B10 Human D-glyceraldehyde increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Glyceraldehyde CTD PMID:19014918 and PMID:19028477 AKR1B10 Human D-glyceraldehyde increases metabolic processing EXP 6480464 AKR1B10 protein results in increased metabolism of Glyceraldehyde CTD PMID:18325492 AKR1B10 Human daunorubicin decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Daunorubicin CTD PMID:19028477 AKR1B10 Human daunorubicin increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Daunorubicin CTD PMID:19028477 AKR1B10 Human daunorubicin multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol more ... CTD PMID:19028477 AKR1B10 Human DDT increases expression EXP 6480464 DDT results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human diarsenic trioxide decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Arsenic Trioxide CTD PMID:20707922 AKR1B10 Human dibenzo[a,l]pyrene decreases expression EXP 6480464 dibenzo(a and l)pyrene results in decreased expression of AKR1B10 mRNA CTD PMID:31255691 AKR1B10 Human diethyl maleate increases expression EXP 6480464 diethyl maleate results in increased expression of AKR1B10 mRNA CTD PMID:33545341 AKR1B10 Human diethylstilbestrol increases expression EXP 6480464 Diethylstilbestrol results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate increases expression EXP 6480464 Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA CTD PMID:28713220 AKR1B10 Human dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate multiple interactions EXP 6480464 [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 AKR1B10 Human diquat increases expression EXP 6480464 Diquat results in increased expression of AKR1B10 mRNA CTD PMID:21172416 AKR1B10 Human disulfiram increases expression EXP 6480464 Disulfiram results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human dorsomorphin multiple interactions EXP 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1B10 mRNA CTD PMID:27188386 AKR1B10 Human doxorubicin decreases response to substance EXP 6480464 AKR1B10 protein results in decreased susceptibility to Doxorubicin CTD PMID:25686905 AKR1B10 Human doxorubicin increases expression EXP 6480464 Doxorubicin results in increased expression of AKR1B10 mRNA CTD PMID:29803840 AKR1B10 Human doxorubicin multiple interactions EXP 6480464 [AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA more ... CTD PMID:25686905 AKR1B10 Human emodin decreases activity EXP 6480464 Emodin results in decreased activity of AKR1B10 protein CTD PMID:35065925 AKR1B10 Human ethanol affects expression ISO Akr1b10 (Mus musculus) 6480464 Ethanol affects the expression of AKR1B10 mRNA CTD PMID:30319688 AKR1B10 Human ethoxyquin increases expression EXP 6480464 Ethoxyquin results in increased expression of AKR1B10 mRNA CTD PMID:21277289 AKR1B10 Human ethoxyquin multiple interactions EXP 6480464 NFE2L2 protein promotes the reaction [Ethoxyquin results in increased expression of AKR1B10 mRNA] CTD PMID:21277289 AKR1B10 Human Ethyl 1-benzyl-3-hydroxy- 2-oxo[5H]pyrrole-4-carboxylate decreases activity EXP 6480464 ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate results in decreased activity of AKR1B10 protein CTD PMID:18325492 AKR1B10 Human Ethyl 1-benzyl-3-hydroxy- 2-oxo[5H]pyrrole-4-carboxylate multiple interactions EXP 6480464 ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] and ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 AKR1B10 Human Ethyl acrylate increases expression EXP 6480464 ethyl acrylate results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human eugenol increases expression EXP 6480464 Eugenol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 more ... AKR1B10 Human farnesal increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of farnesal CTD PMID:21187079 AKR1B10 Human farnesol increases chemical synthesis EXP 6480464 AKR1B10 protein results in increased chemical synthesis of Farnesol CTD PMID:21187079 AKR1B10 Human fenofibrate multiple interactions EXP 6480464 Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] and Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 AKR1B10 Human fenofibrate decreases activity EXP 6480464 Fenofibrate results in decreased activity of AKR1B10 protein and Fenofibrate results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 AKR1B10 Human Fidarestat affects binding EXP 6480464 NADP binds to AKR1B10 protein mutant form binds to fidarestat CTD PMID:23295227 AKR1B10 Human Fidarestat multiple interactions EXP 6480464 fidarestat binds to and results in decreased activity of AKR1B10 protein mutant form CTD PMID:23295227 AKR1B10 Human flucloxacillin increases expression EXP 6480464 Floxacillin results in increased expression of AKR1B10 mRNA CTD PMID:28444390 AKR1B10 Human folpet increases expression ISO Akr1b10 (Mus musculus) 6480464 folpet results in increased expression of AKR1B10 mRNA CTD PMID:31558096 AKR1B10 Human formaldehyde decreases expression EXP 6480464 Formaldehyde results in decreased expression of AKR1B10 mRNA CTD PMID:27664576 AKR1B10 Human formononetin increases expression EXP 6480464 formononetin results in increased expression of AKR1B10 mRNA CTD PMID:37793997 AKR1B10 Human Frangulin A decreases activity EXP 6480464 frangulin A results in decreased activity of AKR1B10 protein CTD PMID:35065925 AKR1B10 Human Frangulin B decreases activity EXP 6480464 frangulin B results in decreased activity of AKR1B10 protein CTD PMID:35065925 AKR1B10 Human furan increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 furan results in increased expression of AKR1B10 mRNA CTD PMID:25539665 AKR1B10 Human gemfibrozil decreases activity EXP 6480464 Gemfibrozil results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 AKR1B10 Human gentamycin increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Gentamicins results in increased expression of AKR1B10 mRNA CTD PMID:33387578 AKR1B10 Human geranylgeraniol increases chemical synthesis EXP 6480464 AKR1B10 protein results in increased chemical synthesis of geranylgeraniol CTD PMID:21187079 AKR1B10 Human glyceraldehyde multiple interactions EXP 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 and PMID:19028477 AKR1B10 Human glyceraldehyde decreases activity EXP 6480464 Glyceraldehyde results in decreased activity of AKR1B10 protein CTD PMID:30469331 AKR1B10 Human glyceraldehyde increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of Glyceraldehyde CTD PMID:19014918 and PMID:19028477 AKR1B10 Human glyceraldehyde increases metabolic processing EXP 6480464 AKR1B10 protein results in increased metabolism of Glyceraldehyde CTD PMID:18325492 AKR1B10 Human gold atom increases expression EXP 6480464 Gold results in increased expression of AKR1B10 mRNA CTD PMID:29705079 AKR1B10 Human gold(0) increases expression EXP 6480464 Gold results in increased expression of AKR1B10 mRNA CTD PMID:29705079 AKR1B10 Human hexane increases expression EXP 6480464 n-hexane results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human hexane-2,3-dione multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of 2 and 3-hexanedione] which results in increased chemical synthesis of Hexanones CTD PMID:23295224 AKR1B10 Human hexane-2,3-dione increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 2 and 3-hexanedione CTD PMID:23295224 AKR1B10 Human hydrogen peroxide affects expression EXP 6480464 Hydrogen Peroxide affects the expression of AKR1B10 mRNA CTD PMID:23410634 AKR1B10 Human hydroquinone decreases expression EXP 6480464 hydroquinone results in decreased expression of AKR1B10 mRNA CTD PMID:31256213 AKR1B10 Human indan-1-ol increases oxidation EXP 6480464 AKR1B10 protein results in increased oxidation of 1-indanol CTD PMID:19013440 AKR1B10 Human indometacin decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Indomethacin results in decreased expression of AKR1B10 mRNA CTD PMID:36868495 AKR1B10 Human isoeugenol increases expression EXP 6480464 isoeugenol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human isoniazide increases expression EXP 6480464 Isoniazid results in increased expression of AKR1B10 mRNA CTD PMID:28444390 AKR1B10 Human Isoxanthohumol decreases activity EXP 6480464 isoxanthohumol results in decreased activity of AKR1B10 protein CTD PMID:35065925 AKR1B10 Human L-ascorbic acid increases expression EXP 6480464 Ascorbic Acid results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human lead diacetate increases expression EXP 6480464 lead acetate results in increased expression of AKR1B10 mRNA CTD PMID:38568856 AKR1B10 Human lead(II) chloride multiple interactions EXP 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA CTD PMID:18654764 AKR1B10 Human lead(II) chloride increases expression EXP 6480464 lead chloride results in increased expression of AKR1B10 mRNA CTD PMID:18654764 AKR1B10 Human Licochalcone B increases expression EXP 6480464 licochalcone B results in increased expression of AKR1B10 mRNA CTD PMID:33647349 AKR1B10 Human lipopolysaccharide increases expression EXP 6480464 Lipopolysaccharides results in increased expression of AKR1B10 mRNA CTD PMID:35811015 AKR1B10 Human lipopolysaccharide multiple interactions EXP 6480464 [S-(1 more ... CTD PMID:35811015 AKR1B10 Human LY294002 decreases expression EXP 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKR1B10 protein CTD PMID:23994249 AKR1B10 Human menadione increases expression EXP 6480464 Vitamin K 3 results in increased expression of AKR1B10 mRNA CTD PMID:23410634 and PMID:34767876 AKR1B10 Human methyl salicylate increases expression EXP 6480464 methyl salicylate results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human methylisothiazolinone increases expression EXP 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of AKR1B10 mRNA CTD PMID:30806763 AKR1B10 Human N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression EXP 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1B10 mRNA CTD PMID:21215737 AKR1B10 Human N-methyl-N-nitrosourea increases expression ISO Akr1b10 (Mus musculus) 6480464 Methylnitrosourea results in increased expression of AKR1B10 mRNA CTD PMID:25270620 AKR1B10 Human N-nitrosodiethylamine multiple interactions ISO Akr1b10 (Rattus norvegicus) 6480464 [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of AKR1B10 mRNA CTD PMID:14656948 AKR1B10 Human N-Nitrosopyrrolidine increases expression EXP 6480464 N-Nitrosopyrrolidine results in increased expression of AKR1B10 mRNA CTD PMID:32234424 AKR1B10 Human NADP zwitterion multiple interactions EXP 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 and PMID:21910479 AKR1B10 Human NADP zwitterion affects binding EXP 6480464 NADP binds to AKR1B10 protein mutant form binds to fidarestat CTD PMID:23295227 AKR1B10 Human NADP zwitterion increases activity EXP 6480464 NADP results in increased activity of AKR1B10 protein CTD PMID:23295224 AKR1B10 Human NADP zwitterion decreases reduction EXP 6480464 AKR1B10 protein results in decreased reduction of NADP CTD PMID:19013440 AKR1B10 Human NADP(+) multiple interactions EXP 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 and PMID:21910479 AKR1B10 Human NADP(+) increases activity EXP 6480464 NADP results in increased activity of AKR1B10 protein CTD PMID:23295224 AKR1B10 Human NADP(+) affects binding EXP 6480464 NADP binds to AKR1B10 protein mutant form binds to fidarestat CTD PMID:23295227 AKR1B10 Human NADP(+) decreases reduction EXP 6480464 AKR1B10 protein results in decreased reduction of NADP CTD PMID:19013440 AKR1B10 Human naphthalenes multiple interactions EXP 6480464 AKR1B10 protein results in increased reduction of and affects the activity of Naphthalenes CTD PMID:21910479 AKR1B10 Human nickel atom increases expression EXP 6480464 Nickel results in increased expression of AKR1B10 mRNA CTD PMID:25583101 AKR1B10 Human nickel sulfate increases expression EXP 6480464 nickel sulfate results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human nitrososulfamethoxazole increases expression EXP 6480464 4-nitrososulfamethoxazole results in increased expression of AKR1B10 mRNA CTD PMID:28444390 AKR1B10 Human Nutlin-3 multiple interactions EXP 6480464 [Dactinomycin co-treated with nutlin 3] results in increased secretion of AKR1B10 protein CTD PMID:38460933 AKR1B10 Human O-methyleugenol increases expression EXP 6480464 methyleugenol results in increased expression of AKR1B10 mRNA CTD PMID:32234424 AKR1B10 Human ochratoxin A decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 ochratoxin A results in decreased expression of AKR1B10 mRNA CTD PMID:18417182 AKR1B10 Human ochratoxin A decreases expression EXP 6480464 ochratoxin A results in decreased expression of AKR1B10 mRNA CTD PMID:32905824 AKR1B10 Human oleanolic acid multiple interactions EXP 6480464 Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA] more ... CTD PMID:25686905 and PMID:27417252 AKR1B10 Human p-chloromercuribenzenesulfonic acid decreases activity EXP 6480464 4-Chloromercuribenzenesulfonate results in decreased activity of AKR1B10 protein CTD PMID:23261715 AKR1B10 Human para-Cresidine increases expression EXP 6480464 cresidine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of AKR1B10 mRNA CTD PMID:21420995 and PMID:29067470 AKR1B10 Human paracetamol decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Acetaminophen results in decreased expression of AKR1B10 mRNA CTD PMID:33387578 AKR1B10 Human paraquat increases expression EXP 6480464 Paraquat results in increased expression of AKR1B10 mRNA CTD PMID:35182771 AKR1B10 Human pazopanib multiple interactions EXP 6480464 pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 AKR1B10 Human pentane-2,3-dione multiple interactions EXP 6480464 [AKR1B10 protein results in increased reduction of 2 and 3-pentanedione] which results in increased chemical synthesis of Pentanones CTD PMID:23295224 AKR1B10 Human pentane-2,3-dione increases reduction EXP 6480464 AKR1B10 protein results in increased reduction of 2 and 3-pentanedione CTD PMID:23295224 AKR1B10 Human perfluorohexanesulfonic acid increases expression ISO Akr1b10 (Mus musculus) 6480464 perfluorohexanesulfonic acid results in increased expression of AKR1B10 mRNA CTD PMID:37995155 AKR1B10 Human perfluorooctane-1-sulfonic acid increases expression EXP 6480464 perfluorooctane sulfonic acid results in increased expression of AKR1B10 mRNA CTD PMID:27153767 AKR1B10 Human perfluorooctanoic acid increases expression EXP 6480464 perfluorooctanoic acid results in increased expression of AKR1B10 mRNA and perfluorooctanoic acid results in increased expression of AKR1B10 protein CTD PMID:26879310 and PMID:27153767 AKR1B10 Human phenethyl caffeate decreases activity EXP 6480464 caffeic acid phenethyl ester results in decreased activity of AKR1B10 protein CTD PMID:27163852 AKR1B10 Human phenobarbital affects expression EXP 6480464 Phenobarbital affects the expression of AKR1B10 mRNA CTD PMID:19084549 AKR1B10 Human phenobarbital increases expression EXP 6480464 Phenobarbital results in increased expression of AKR1B10 protein CTD PMID:35881160 AKR1B10 Human phenol increases expression EXP 6480464 Phenol results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human phenylmercury acetate increases expression EXP 6480464 Phenylmercuric Acetate results in increased expression of AKR1B10 mRNA CTD PMID:26272509 AKR1B10 Human phenylmercury acetate multiple interactions EXP 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1B10 mRNA CTD PMID:27188386 AKR1B10 Human phorbol 13-acetate 12-myristate multiple interactions EXP 6480464 [Tetradecanoylphorbol Acetate results in increased expression of JUN mRNA] which results in decreased expression of AKR1B10 mRNA and U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of AKR1B10 mRNA] CTD PMID:25463304 AKR1B10 Human phorbol 13-acetate 12-myristate decreases expression EXP 6480464 Tetradecanoylphorbol Acetate results in decreased expression of AKR1B10 mRNA and Tetradecanoylphorbol Acetate results in decreased expression of AKR1B10 protein CTD PMID:25463304 and PMID:26198647 AKR1B10 Human picoxystrobin decreases expression EXP 6480464 picoxystrobin results in decreased expression of AKR1B10 mRNA CTD PMID:33512557 AKR1B10 Human pimecrolimus multiple interactions EXP 6480464 pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 AKR1B10 Human pirinixic acid multiple interactions EXP 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of AKR1B10 mRNA more ... CTD PMID:19028477 and PMID:19710929 AKR1B10 Human pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human pirinixic acid multiple interactions ISO Akr1b10 (Mus musculus) 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of AKR1B10 mRNA CTD PMID:19710929 AKR1B10 Human pirinixic acid decreases activity EXP 6480464 pirinixic acid results in decreased activity of AKR1B10 protein and pirinixic acid results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 AKR1B10 Human potassium bromate multiple interactions ISO Akr1b10 (Mus musculus) 6480464 [potassium bromate co-treated with bisphenol A] affects the expression of AKR1B10 mRNA more ... CTD PMID:27082013 AKR1B10 Human potassium bromate affects expression ISO Akr1b10 (Mus musculus) 6480464 potassium bromate affects the expression of AKR1B10 mRNA CTD PMID:27082013 AKR1B10 Human progesterone multiple interactions EXP 6480464 [Progesterone co-treated with Estradiol] results in decreased expression of AKR1B10 mRNA CTD PMID:17404688 AKR1B10 Human progesterone decreases expression EXP 6480464 Progesterone results in decreased expression of AKR1B10 mRNA CTD PMID:17404688 AKR1B10 Human propan-2-ol increases expression EXP 6480464 2-Propanol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human propiconazole multiple interactions EXP 6480464 [propiconazole co-treated with tebuconazole] results in increased expression of AKR1B10 mRNA CTD PMID:30989312 AKR1B10 Human propiconazole increases expression EXP 6480464 propiconazole results in increased expression of AKR1B10 mRNA CTD PMID:30989312 AKR1B10 Human quercetin decreases expression EXP 6480464 Quercetin results in decreased expression of AKR1B10 mRNA CTD PMID:21632981 AKR1B10 Human quercetin increases expression EXP 6480464 Quercetin results in increased expression of AKR1B10 mRNA CTD PMID:34767876 AKR1B10 Human quinolin-8-ol increases expression EXP 6480464 Oxyquinoline results in increased expression of AKR1B10 mRNA CTD PMID:21632981 and PMID:26198647 AKR1B10 Human rac-lactic acid increases expression EXP 6480464 Lactic Acid results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human rac-lactic acid decreases expression EXP 6480464 Lactic Acid results in decreased expression of AKR1B10 mRNA CTD PMID:30851411 AKR1B10 Human reserpine increases expression EXP 6480464 Reserpine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human resorcinol increases expression EXP 6480464 resorcinol results in increased expression of AKR1B10 mRNA CTD PMID:22623647 more ... AKR1B10 Human resveratrol multiple interactions ISO Akr1b10 (Mus musculus) 6480464 [resveratrol co-treated with HMGB1 protein] results in increased expression of AKR1B10 mRNA CTD PMID:25979658 AKR1B10 Human rifampicin increases expression EXP 6480464 Rifampin results in increased expression of AKR1B10 mRNA CTD PMID:29356861 AKR1B10 Human rifampicin multiple interactions EXP 6480464 pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] and pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 AKR1B10 Human rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of AKR1B10 mRNA CTD PMID:33512557 AKR1B10 Human S-(1,2-dichlorovinyl)-L-cysteine increases expression EXP 6480464 S-(1 and 2-dichlorovinyl)cysteine results in increased expression of AKR1B10 mRNA CTD PMID:35811015 AKR1B10 Human S-(1,2-dichlorovinyl)-L-cysteine multiple interactions EXP 6480464 [S-(1 more ... CTD PMID:35811015 AKR1B10 Human SB 431542 multiple interactions EXP 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1B10 mRNA CTD PMID:27188386 AKR1B10 Human silicon dioxide decreases expression EXP 6480464 Silicon Dioxide analog results in decreased expression of AKR1B10 mRNA CTD PMID:25895662 AKR1B10 Human silicon dioxide decreases expression ISO Akr1b10 (Mus musculus) 6480464 Silicon Dioxide results in decreased expression of AKR1B10 mRNA CTD PMID:19073995 AKR1B10 Human silicon dioxide increases secretion EXP 6480464 Silicon Dioxide analog results in increased secretion of AKR1B10 protein CTD PMID:25895662 AKR1B10 Human silver atom increases expression EXP 6480464 Silver results in increased expression of AKR1B10 mRNA CTD PMID:26014281 AKR1B10 Human silver(0) increases expression EXP 6480464 Silver results in increased expression of AKR1B10 mRNA CTD PMID:26014281 AKR1B10 Human sodium arsenate multiple interactions EXP 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA CTD PMID:32525701 AKR1B10 Human sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of AKR1B10 mRNA CTD PMID:23876855 more ... AKR1B10 Human sodium arsenite decreases expression ISO Akr1b10 (Mus musculus) 6480464 sodium arsenite results in decreased expression of AKR1B10 mRNA CTD PMID:37682722 AKR1B10 Human sodium arsenite multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 AKR1B10 Human sodium dodecyl sulfate increases expression EXP 6480464 Sodium Dodecyl Sulfate results in increased expression of AKR1B10 mRNA CTD PMID:20566472 and PMID:30806763 AKR1B10 Human sorbinil multiple interactions EXP 6480464 sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin] and sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 AKR1B10 Human sorbinil decreases activity EXP 6480464 sorbinil results in decreased activity of AKR1B10 protein CTD PMID:18325492 AKR1B10 Human sulforaphane increases expression EXP 6480464 sulforaphane results in increased expression of AKR1B10 mRNA CTD PMID:24383545 more ... AKR1B10 Human sulindac multiple interactions EXP 6480464 Sulindac analog binds to and results in decreased activity of AKR1B10 protein and Sulindac binds to and results in decreased activity of AKR1B10 protein CTD PMID:25532697 AKR1B10 Human sulindac sulfone multiple interactions EXP 6480464 sulindac sulfone binds to and results in decreased activity of AKR1B10 protein CTD PMID:25532697 AKR1B10 Human tebuconazole multiple interactions EXP 6480464 [propiconazole co-treated with tebuconazole] results in increased expression of AKR1B10 mRNA CTD PMID:30989312 AKR1B10 Human tebuconazole increases expression EXP 6480464 tebuconazole results in increased expression of AKR1B10 mRNA CTD PMID:30989312 AKR1B10 Human temozolomide decreases expression EXP 6480464 Temozolomide results in decreased expression of AKR1B10 mRNA CTD PMID:31758290 AKR1B10 Human tert-butyl hydroperoxide increases expression EXP 6480464 tert-Butylhydroperoxide results in increased expression of AKR1B10 mRNA CTD PMID:23410634 and PMID:34767876 AKR1B10 Human tetraphene increases expression EXP 6480464 benz(a)anthracene results in increased expression of AKR1B10 mRNA CTD PMID:22236718 AKR1B10 Human thioacetamide increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Thioacetamide results in increased expression of AKR1B10 mRNA CTD PMID:23411599 and PMID:34492290 AKR1B10 Human titanium dioxide decreases phosphorylation EXP 6480464 titanium dioxide results in decreased phosphorylation of AKR1B10 protein CTD PMID:21439344 AKR1B10 Human trans-isoeugenol increases expression EXP 6480464 isoeugenol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 AKR1B10 Human Tributyltin oxide increases expression EXP 6480464 bis(tri-n-butyltin)oxide results in increased expression of AKR1B10 mRNA CTD PMID:26198647 AKR1B10 Human trichloroethene increases expression ISO Akr1b10 (Rattus norvegicus) 6480464 Trichloroethylene results in increased expression of AKR1B10 mRNA CTD PMID:33387578 AKR1B10 Human Triptolide decreases expression ISO Akr1b10 (Rattus norvegicus) 6480464 triptolide results in decreased expression of AKR1B10 protein CTD PMID:32519852 AKR1B10 Human troglitazone increases expression EXP 6480464 troglitazone results in increased expression of AKR1B10 mRNA CTD PMID:25572481 AKR1B10 Human urethane decreases expression EXP 6480464 Urethane results in decreased expression of AKR1B10 mRNA CTD PMID:28818685 AKR1B10 Human valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of AKR1B10 mRNA CTD PMID:29154799 AKR1B10 Human valproic acid affects expression EXP 6480464 Valproic Acid affects the expression of AKR1B10 mRNA CTD PMID:25979313 AKR1B10 Human vitamin E increases expression EXP 6480464 Vitamin E results in increased expression of AKR1B10 mRNA CTD PMID:34767876
